-
Scopus BioPharma Seeks $6 Million U.S. IPO
Post on 7/30/20
-
BioXcel Therapeutics Prices Public Offering of Common Stock
Post on 7/29/20
-
Don’t Delay! Northern Westchester Hospital Urges Cancer Patients to Discuss Treatment with Physicians
Post on 7/29/20
-
Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial
Post on 7/29/20
-
How Pfizer Beat Q2 Estimates Despite Upjohn Sales Plunging 31%
Post on 7/29/20
-
Pfizer Rises 4.5% on Q2 Beats, Raised Guidance
Post on 7/29/20
-
Merck Declares Fresh Dividend; Yield Is 3.1%
Post on 7/29/20
-
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
Post on 7/29/20
-
Will Regeneron Help Win the Fight Against COVID-19?
Post on 7/29/20
-
Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company
Post on 7/28/20
-
CorMedix Prices $20M Public Offering of Common Stock
Post on 7/28/20
-
Viva Biotech and Schrödinger Announce Strategic Collaboration
Post on 7/28/20
-
WindRose Health Investors Invests in Caregiver
Post on 7/28/20
-
DriveWealth Partners with MotivHealth
Post on 7/28/20
-
Karuna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
Post on 7/28/20
-
Pfizer Reports Second-Quarter 2020 Results
Post on 7/28/20
-
Pfizer, BioNTech Choose Coronavirus Vaccine Candidate to Advance to Phase 2/3 Trial
Post on 7/28/20
-
3 Numbers to Watch When Teladoc Releases Earnings This Week
Post on 7/28/20
-
CorMedix Proposes Public Offering of Common Stock
Post on 7/27/20
-
BioXcel Therapeutics Proposes Public Offering of Common Stock
Post on 7/27/20
-
Zentalis Pharmaceuticals Proposes Public Offering of Common Stock
Post on 7/27/20
-
Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi
Post on 7/27/20
-
BioHiTech Global Announces Pricing of $8.2 Million Public Offering of Common Stock
Post on 7/27/20
-
CipherHealth Recognized as One of the Best Places to Work by Modern Healthcare for the Sixth Time
Post on 7/27/20
-
BrainStorm Cell Therapeutics to Provide a Corporate and R&D Update
Post on 7/27/20
New York
